List view / Grid view

Glaucoma

Filter the results

 

article

How implantable systems and microparticle depot injections are meeting the needs of long-acting drug delivery

26 June 2020 | By ,

Implantable systems and microparticle depots are used in many areas of drug delivery to release medicines at a controlled rate within the body. The use of these long-acting dosage forms eliminates the need for frequent administrations via traditional routes of administration, which ensures patient compliance and results in improved outcomes.…

news

Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology

18 April 2017 | By Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).

news

Santen establishes subsidiary in United Kingdom

4 November 2014 | By Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...